Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia
| Status: | Completed |
|---|---|
| Conditions: | Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 3/30/2019 |
| Start Date: | October 2011 |
| End Date: | May 2018 |
The investigators hypothesize that Lipoprotein Lipase (LPL) expression on Chronic Lymphocytic
Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this
proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL
and will predict CLL patients that have a more aggressive form of the disease. The
investigators work will also provide direct evidence that LPL is expressed on CLL cells and
provides a critical source of fatty acids required by the CLL cells to grow and survive.
Fatty acid metabolism may become a therapeutic target in CLL in the future.
Leukemia (CLL) cells will predict a more aggressive clinical course. The results from this
proposal will validate the use of a novel antibody developed at Dartmouth-Hitchcock in CLL
and will predict CLL patients that have a more aggressive form of the disease. The
investigators work will also provide direct evidence that LPL is expressed on CLL cells and
provides a critical source of fatty acids required by the CLL cells to grow and survive.
Fatty acid metabolism may become a therapeutic target in CLL in the future.
The investigators plan to use a novel antibody developed at Dartmouth-Hitchcock Medical
Center to characterize the expression of LPL in CLL. Peripheral blood from CLL patients will
be analyzed by flow cytometry to detect the expression of LPL and to investigate if LPL
expression correlates with a more aggressive type of CLL. The investigators propose that LPL
protein expression on CLL cells is prognostic and that LPL and other proteins involved in
fatty acid metabolism are critical for CLL cells to survive.
Center to characterize the expression of LPL in CLL. Peripheral blood from CLL patients will
be analyzed by flow cytometry to detect the expression of LPL and to investigate if LPL
expression correlates with a more aggressive type of CLL. The investigators propose that LPL
protein expression on CLL cells is prognostic and that LPL and other proteins involved in
fatty acid metabolism are critical for CLL cells to survive.
Inclusion Criteria:
- Diagnosis of CLL as per National Cancer Institute Working Group Guidelines
- Patients undergoing routine blood draws as part of their ongoing follow up for CLL
- 18 years or older
- Ability to provide consent in English
- Patient must have measurable disease as defined by an absolute lymphocyte count
greater than 5,000/mm3 or have archived lymph node or bone marrow with CLL
involvement.
Exclusion Criteria:
- Patients who have received cytotoxic drug, oral or intravenous steroid or targeted
antibody therapy for their CLL,
- other hematologic malignancy or other disease process within the past 6 months are
excluded.
We found this trial at
1
site
Dartmouth Hitchcock Medical Center Dartmouth-Hitchcock is a national leader in patient-centered health care and building...
Click here to add this to my saved trials
